Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Correction: Complete remission of seronegative rheumatoid arthritis following haplo-identical stem cell transplantation for peripheral T-cell lymphoma.

Atoui A, El Labban M, Ghaoui N, El Darsa H, El Cheikh J, Bazarbachi A.

Bone Marrow Transplant. 2019 Oct 4. doi: 10.1038/s41409-019-0706-y. [Epub ahead of print]

PMID:
31586131
2.

Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study.

Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gülbas Z, Wallet HL, Corral LL, Mohty M, Koc Y, Yakoub-Agha I, Schmid C, El Cheikh J, Arat M, Forcade E, Dreger P, Rocha V, García GG, Chalandon Y, Ferra C, Orvain C, Robinson S, Montoto S, Sureda A.

Br J Haematol. 2019 Sep 9. doi: 10.1111/bjh.16182. [Epub ahead of print]

PMID:
31498883
3.

Complete remission of seronegative rheumatoid arthritis following haplo-identical stem cell transplantation for peripheral T-cell lymphoma.

Atoui A, El Labban M, Ghaoui N, El Darsa H, El Cheikh J, Bazarbachi A.

Bone Marrow Transplant. 2019 Aug 12. doi: 10.1038/s41409-019-0635-9. [Epub ahead of print] No abstract available. Erratum in: Bone Marrow Transplant. 2019 Oct 4;:.

PMID:
31406225
4.

Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness.

Boileau M, Shirinian M, Gayden T, Harutyunyan AS, Chen CCL, Mikael LG, Duncan HM, Neumann AL, Arreba-Tutusaus P, De Jay N, Zeinieh M, Rossokhata K, Zhang Y, Nikbakht H, Mouawad C, Massoud R, Frey F, Nasr R, El Cheikh J, El Sabban M, Kleinman CL, Mahfouz R, Minden MD, Jabado N, Bazarbachi A, Eppert K.

Nat Commun. 2019 Jun 28;10(1):2891. doi: 10.1038/s41467-019-10705-z.

5.

Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.

Battipaglia G, Massoud R, Ahmed SO, Legrand O, El Cheikh J, Youniss R, Aljurf M, Mohty M, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):506-508. doi: 10.1016/j.clml.2019.04.004. Epub 2019 Apr 18.

PMID:
31122828
6.

Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological malignancy: a prospective, observational study in France.

El Cheikh J, Ceballos P, Dalle JH, Ducastelle-Leprêtre S, Dulon E, Herbrecht R.

Diagn Microbiol Infect Dis. 2019 Jul;94(3):268-273. doi: 10.1016/j.diagmicrobio.2019.01.011. Epub 2019 Jan 26.

7.

Successful treatment of severe aplastic anemia with syngeneic stem cell transplantation in the setting of active disseminated mucormycosis.

El-Cheikh J, Atoui A, Moukalled N, Ghaoui N, El Darsa H, Kanj SS, Bazarbachi A.

Med Mycol Case Rep. 2019 Jan 12;23:68-71. doi: 10.1016/j.mmcr.2019.01.001. eCollection 2019 Mar.

8.

Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.

Assaf N, El-Cheikh J, Bazarbachi A, Salem Z, Farra C, Chakhachiro Z, Nassif S, Zaatari G, Mahfouz R.

Mol Biol Rep. 2019 Apr;46(2):2003-2011. doi: 10.1007/s11033-019-04649-2. Epub 2019 Jan 30.

PMID:
30701458
9.

Correction to: Mucormycosis in hospitalized patients at a tertiary care center in Lebanon: a case series.

Zein SE, El-Cheikh J, Zakhem AE, Ibrahim D, Bazarbachi A, Kanj SS.

Infection. 2019 Apr;47(2):335. doi: 10.1007/s15010-018-1259-5.

PMID:
30617837
10.

Sarcopenic obesity derived from PET/CT predicts mortality in lymphoma patients undergoing hematopoietic stem cell transplantation.

Jabbour J, Manana B, Zahreddine A, Saade C, Charafeddine M, Bazarbachi A, Blaise D, El-Cheikh J.

Curr Res Transl Med. 2019 Aug;67(3):93-99. doi: 10.1016/j.retram.2018.12.001. Epub 2018 Dec 21.

PMID:
30583985
11.

[Donor Lymphocyte Infusions (DLI): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

De Vos J, Baudoux E, Bay JO, Calmels B, Cras A, El Cheikh J, Guerout-Verite MA, Lacassagne MN, Lamure S, Letellier C, Menard AL, Daguindau E, Poiré X, Yakoub-Agha I, Guillaume T.

Bull Cancer. 2019 Jan;106(1S):S35-S39. doi: 10.1016/j.bulcan.2018.10.002. Epub 2018 Dec 20. French.

PMID:
30580911
12.

Haploidentical related donor allogeneic hematopoietic stem cell transplantation for patient aged older than 76 years with refractory acute myeloid leukemia.

El-Cheikh J, Salem R, Massoud R, Salem C, Ghaoui N, Kanj SS, Mahfouz R, Bazarbachi A.

Hematol Oncol Stem Cell Ther. 2018 Dec 9. pii: S1658-3876(18)30119-5. doi: 10.1016/j.hemonc.2018.11.005. [Epub ahead of print] No abstract available.

13.

[Graft reinjection: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Tarillon S, Andrianne C, Balcaen S, Bole S, Genty C, Godin S, Lemarchand E, Mouchebeuf J, Mussot I, Wallart A, Alsuliman T, Desbrosses Y, El Cheikh J, Guerout-Verite MA, De Vos J, Tardieu L, Yakoub-Agha I, Porcheron S.

Bull Cancer. 2019 Jan;106(1S):S83-S91. doi: 10.1016/j.bulcan.2018.11.001. Epub 2018 Dec 7. French.

PMID:
30528618
14.

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Diez-Martin JL, Corradini P, Michonneau D, Robinson S, Gutiérrez García G, Bonifazi F, Yakoub-Agha I, Gülbas Z, Bloor A, Delage J, Esquirol A, Malladi R, Scheid C, El-Cheikh J, Ghesquières H, Montoto S, Dreger P, Sureda A.

Cancer. 2019 Jan 1;125(1):90-98. doi: 10.1002/cncr.31755. Epub 2018 Oct 23.

15.

The impact of counseling on nutritional status among hematopoietic stem cell recipients: results of a randomized controlled trial.

Jabbour J, Manana B, Sakr M, Zahreddine A, Tamim H, Bazarbachi A, Blaise D, El-Cheikh J.

Bone Marrow Transplant. 2019 May;54(5):752-756. doi: 10.1038/s41409-018-0366-3. Epub 2018 Oct 22. No abstract available.

PMID:
30349039
16.

Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation.

Moukalled NM, El Darsa H, Haibe Y, Massoud R, Kanj SS, Mahfouz R, Bazarbachi A, El-Cheikh J.

Bone Marrow Transplant. 2019 Apr;54(4):620-624. doi: 10.1038/s41409-018-0347-6. Epub 2018 Oct 4. No abstract available.

PMID:
30287936
17.

Site specific diagnostic yield of endoscopic biopsies in Gastrointestinal Graft-versus-Host Disease: A tertiary care Center experience.

Daniel F, Hassoun L, Husni M, Sharara A, Soweid A, Barada K, Haffar B, Massoud R, Shaib Y, Al-Hashash J, Bazarbachi A, El Cheikh J.

Curr Res Transl Med. 2019 Feb;67(1):16-19. doi: 10.1016/j.retram.2018.08.001. Epub 2018 Sep 8.

PMID:
30206046
18.

Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

El-Cheikh J, Moukalled NM, El Darsa H, Massoud R, Kanj SS, Mahfouz R, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e441-e444. doi: 10.1016/j.clml.2018.07.289. Epub 2018 Aug 27. No abstract available.

PMID:
30166258
19.

Mucormycosis in hospitalized patients at a tertiary care center in Lebanon: a case series.

El Zein S, El-Cheikh J, El Zakhem A, Ibrahim D, Bazarbachi A, Kanj SS.

Infection. 2018 Dec;46(6):811-821. doi: 10.1007/s15010-018-1195-4. Epub 2018 Aug 18. Erratum in: Infection. 2018 Sep 14;:. Infection. 2019 Jan 7;:.

PMID:
30121719
20.

Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study.

Gangneux JP, El Cheikh J, Herbrecht R, Yakoub-Agha I, Quiniou JB, Caillot D, Michallet M.

Infect Dis Ther. 2018 Sep;7(3):309-325. doi: 10.1007/s40121-018-0203-4. Epub 2018 Jun 9.

21.

Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation.

El-Cheikh J, Massoud R, Moukalled N, Haffar B, Assi H, Zahreddine A, Mahfouz R, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):368-374. doi: 10.1016/j.clml.2018.02.016. Epub 2018 Mar 1.

PMID:
29625929
22.

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A.

Br J Haematol. 2018 Apr;181(1):86-96. doi: 10.1111/bjh.15152. Epub 2018 Feb 22.

PMID:
29468647
23.

Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT.

Castagna L, Boubdallah R, Furst S, Coso D, El Cheikh J, Faucher C, Crocchiolo R, Granata A, Chabannon C, Lemarié C, Calmels B, Boher JM, Mohty M, Blaise D.

Bone Marrow Transplant. 2018 Feb;53(2):234. doi: 10.1038/bmt.2018.1.

PMID:
29410535
24.

Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.

Duléry R, Ménard AL, Chantepie S, El-Cheikh J, François S, Delage J, Giannotti F, Ruggeri A, Brissot E, Battipaglia G, Malard F, Belhocine R, Sestili S, Vekhoff A, Delhommeau F, Reman O, Legrand O, Labopin M, Rubio MT, Mohty M.

Biol Blood Marrow Transplant. 2018 May;24(5):1013-1021. doi: 10.1016/j.bbmt.2018.01.005. Epub 2018 Jan 11.

25.

Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.

Mariotti J, Bramanti S, Devillier R, Furst S, El Cheikh J, Sarina B, Granata A, Faucher C, Harbi S, Morabito L, Weiller PJ, Chabannon C, Mokart J, Mineri R, Carlo-Stella C, Santoro A, Blaise D, Castagna L.

Bone Marrow Transplant. 2018 Mar;53(3):366-370. doi: 10.1038/s41409-017-0032-1. Epub 2017 Dec 21. No abstract available.

PMID:
29269800
26.

Progressive multifocal leukoencephalopathy in patients receiving rituximab and cyclophosphamide after haplo-identical T-cell replete transplantation and review of the literature.

Salem R, Massoud R, Kanj SS, Hamdan M, Salman R, Bazarbachi A, El-Cheikh J.

Curr Res Transl Med. 2017 Nov;65(4):127-132. doi: 10.1016/j.retram.2017.10.002. Epub 2017 Nov 10. Review.

PMID:
29132903
27.

Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.

Massoud R, Assi R, Fares E, Haffar B, Charafeddine M, Kreidieh N, Mahfouz R, Kanj SS, El Zakhem A, Kharfan-Dabaja M, Bazarbachi A, El Cheikh J.

J Clin Virol. 2017 Oct;95:36-41. doi: 10.1016/j.jcv.2017.08.006. Epub 2017 Aug 18.

PMID:
28843110
28.

Trends in hematopoietic stem cell transplant activity in Lebanon.

Bazarbachi A, Zahreddine A, Massoud R, El Cheikh J, Hanna C, Nasr F, Abboud M, Ibrahim A.

Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):315-320. doi: 10.1016/j.hemonc.2017.05.003. Epub 2017 Jun 13.

29.

Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant.

Salem R, Massoud R, Haffar B, Mahfouz R, Bazarbachi A, El-Cheikh J.

Bone Marrow Transplant. 2017 Aug;52(8):1187-1190. doi: 10.1038/bmt.2017.82. Epub 2017 Jun 5. No abstract available.

PMID:
28581462
30.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.

Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, El-Cheikh J, Granata A, Faucher C, Harbi S, Morabito L, Mariotti J, Puvinathan S, Weiller PJ, Chabannon C, Mokart D, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):797. doi: 10.1038/bmt.2017.26. No abstract available.

PMID:
28465624
31.

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.

Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, Fegueux N, Tabrizi R, Finke J, El-Cheikh J, Schipperus M, Meijer E, von dem Borne P, Petersen E, Russell N, Tholouli E, Passweg J, Garban F, Maertens J, Chevalier P, Maillard N, Volin L, Francois S, Lioure B, Beguin Y, Gluckman E, Ruggeri A, Garderet L, Kröger N.

Haematologica. 2017 Jul;102(7):e271-e274. doi: 10.3324/haematol.2017.165399. Epub 2017 Apr 20. No abstract available.

32.

Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma.

El Cheikh J, Massoud R, Abudalle I, Haffar B, Mahfouz R, Kharfan-Dabaja MA, Jisr T, Mougharbel A, Ibrahim A, Bazarbachi A.

Bone Marrow Transplant. 2017 Jul;52(7):1074-1077. doi: 10.1038/bmt.2017.69. Epub 2017 Apr 10. No abstract available.

PMID:
28394366
33.

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.

Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A.

Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7.

34.

Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT.

El-Cheikh J, Massoud R, Fares E, Kreidieh N, Mahfouz R, Charafeddine M, Kharfan-Dabaja MA, Bazarbachi A.

Bone Marrow Transplant. 2017 Jun;52(6):918-921. doi: 10.1038/bmt.2017.31. Epub 2017 Apr 3. No abstract available.

PMID:
28368381
35.

Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.

El Cheikh J, Massoud R, Haffar B, Fares E, Mahfouz R, Jisr T, Kharfan-Dabaja MA, Mougharbel A, Youssef A, Bazarbachi A, Ibrahim A.

Leuk Lymphoma. 2017 Nov;58(11):2745-2747. doi: 10.1080/10428194.2017.1307362. Epub 2017 Mar 28. No abstract available.

PMID:
28351183
36.

PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma.

El Karak F, Bou-Orm IR, Ghosn M, Kattan J, Farhat F, Ibrahim T, Jreige M, El Cheikh J, Haidar M.

PLoS One. 2017 Jan 18;12(1):e0170299. doi: 10.1371/journal.pone.0170299. eCollection 2017.

37.

Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT.

Battipaglia G, Labopin M, Candoni A, Fanin R, El Cheikh J, Blaise D, Michallet M, Ruggeri A, Contentin N, Ribera JM, Stadler M, Sierra J, von dem Borne PA, Bloor A, Socié G, Nagler A, Mohty M.

Bone Marrow Transplant. 2017 Apr;52(4):592-599. doi: 10.1038/bmt.2016.302. Epub 2017 Jan 16.

PMID:
28092357
38.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.

Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, El-Cheikh J, Granata A, Faucher C, Harbi S, Morabito L, Mariotti J, Puvinathan S, Weiller PJ, Chabannon C, Mokart D, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):683-688. doi: 10.1038/bmt.2016.348. Epub 2017 Jan 16. Erratum in: Bone Marrow Transplant. 2017 May;52(5):797.

PMID:
28092347
39.

Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.

El-Cheikh J, El Dika I, Massoud R, Charafeddine M, Mahfouz R, Kharfan-Dabaja MA, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):179-185. doi: 10.1016/j.clml.2016.11.002. Epub 2016 Nov 21.

PMID:
27988194
40.

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML.

Legrand F, Le Floch AC, Granata A, Fürst S, Faucher C, Lemarie C, Harbi S, Bramanti S, Calmels B, El-Cheikh J, Chabannon C, Weiller PJ, Vey N, Castagna L, Blaise D, Devillier R.

Bone Marrow Transplant. 2017 Apr;52(4):620-621. doi: 10.1038/bmt.2016.326. Epub 2016 Dec 12. No abstract available.

PMID:
27941765
41.

Inhibition of FLT3 in AML: a focus on sorafenib.

Antar A, Otrock ZK, El-Cheikh J, Kharfan-Dabaja MA, Battipaglia G, Mahfouz R, Mohty M, Bazarbachi A.

Bone Marrow Transplant. 2017 Mar;52(3):344-351. doi: 10.1038/bmt.2016.251. Epub 2016 Oct 24. Review.

PMID:
27775694
42.

A Single Mass Forming Colonic Primary Mantle Cell Lymphoma.

Daniel F, Assi HI, Karaoui W, El Cheikh J, Bannoura S, Nassif S.

Case Rep Gastrointest Med. 2016;2016:2561507. doi: 10.1155/2016/2561507. Epub 2016 Aug 4.

43.

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.

Mohty M, Malard F, Blaise D, Milpied N, Socié G, Huynh A, Reman O, Yakoub-Agha I, Furst S, Guillaume T, Tabrizi R, Vigouroux S, Peterlin P, El-Cheikh J, Moreau P, Labopin M, Chevallier P.

Haematologica. 2017 Jan;102(1):184-191. doi: 10.3324/haematol.2016.150326. Epub 2016 Aug 25.

44.

The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.

Rimondo A, Crocchiolo R, El-Cheikh J, Bramanti S, Granata A, Furst S, Sarina B, Morabito L, Devillier R, Harbi S, Mohty B, Mineri R, Faucher C, Chabannon C, Santoro A, Blaise D, Castagna L.

Bone Marrow Transplant. 2017 Jan;52(1):135-137. doi: 10.1038/bmt.2016.193. Epub 2016 Jul 18. No abstract available.

PMID:
27427919
45.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N.

Leukemia. 2016 Oct;30(10):2047-2054. doi: 10.1038/leu.2016.101. Epub 2016 Apr 27.

46.

The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.

Crocchiolo R, Castagna L, Furst S, Devillier R, Sarina B, Bramanti S, El-Cheikh J, Granata A, Harbi S, Morabito L, Faucher C, Rimondo A, Girardi D, Mohty B, Calmels B, Carlo-Stella C, Chabannon C, Bouabdallah R, Santoro A, Vey N, Weiller PJ, Blaise D.

Bone Marrow Transplant. 2016 Aug;51(8):1134-6. doi: 10.1038/bmt.2016.69. Epub 2016 Mar 21. No abstract available.

PMID:
26999460
47.

Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC).

El Cheikh J, Sfumato P, Sobh M, Fegueux N, Mohty M, Vigouroux S, Beguin Y, Yakoub-Agha I, Socié G, Cornillon J, Mercier M, Bay JO, Blaise D, Michallet M, Peffault de Latour R.

Haematologica. 2016 Jun;101(6):e262-5. doi: 10.3324/haematol.2015.139345. Epub 2016 Mar 18. No abstract available.

48.

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.

Castagna L, Bramanti S, Furst S, Giordano L, Sarina B, Crocchiolo R, El-Cheikh J, Granata A, Morabito L, Mauro E, Faucher C, Mohty B, Harbi S, Devillier R, Chabannon C, Carlo-Stella C, Santoro A, Blaise D.

Bone Marrow Transplant. 2016 Mar;51(3):470. doi: 10.1038/bmt.2015.327. No abstract available.

PMID:
26931485
49.

Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions.

El Cheikh J, Otrock ZK, Qannus AA, Kharfan-Dabaja MA, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2016 May;16(5):304-10. doi: 10.1016/j.clml.2016.01.005. Epub 2016 Feb 4.

PMID:
26923326
50.

The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia.

Wanquet A, Crocchiolo R, Furst S, Granata A, Faucher C, Devillier R, Harbi S, Lemarie C, Calmels B, Vey N, Weiller PJ, Chabannon C, Castagna L, Blaise D, El-Cheikh J.

Leuk Lymphoma. 2016 Oct;57(10):2315-20. doi: 10.3109/10428194.2016.1146948. Epub 2016 Feb 17.

PMID:
26885686

Supplemental Content

Loading ...
Support Center